SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)-SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN

被引：47

作者：

Lagos, Rosanna ^{[3
]}

DeVincenzo, John P. ^{[2
]}

Munoz, Alma ^{[3
]}

Hultquist, Micki ^{[1
]}

Suzich, Joann ^{[1
]}

Connor, Edward M. ^{[1
]}

Losonsky, Genevieve A. ^{[1
]}

机构：

[1] MedImmune LLC, Gaithersburg, MD 20878 USA

[2] Univ Tennessee, Childrens Fdn Res Ctr, Sch Med, Memphis, TN USA

[3] Ctr Para Vacunas En Desarrollo Chile, Santiago, Chile

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2009年 / 28卷 / 09期

关键词：

antibodies; bronchiolitis; monoclonal; antiviral agents clinical trial; motavizumab; pediatric; respiratory syncytial virus; viral load; DISEASE SEVERITY; PREVENTION; IMBALANCE; INFANTS; LOAD;

D O I：

10.1097/INF.0b013e3181a165e4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.

引用

页码：835 / 837

页数：3

共 15 条

[1] Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children
Abarca, Katia
Jung, Elizabeth
Fernandez, Pilar
Zhao, Liang
Harris, Brian
Connor, Edward M.
Losonsky, Genevieve A.
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) : 267 - 272
[2] Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: An experimental murine model
Chavez-Bueno, Susana
Mejias, Asuncion
Gomez, Ana M.
Olsen, Kurt D.
Rios, Ana M.
Fonseca-Aten, Monica
Ramilo, Octavio
Jafri, Hasan S.
[J]. VIROLOGY JOURNAL, 2005, 2 (1)
[3] DEVINCENZO J, 2007, 47 ANN ICAAC SEPT 17
[4] Respiratory syncytial virus load predicts disease severity in previously healthy infants
DeVincenzo, JP
El Saleeby, CM
Bush, AJ
[J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) : 1861 - 1868
[5] Natural infection of infants with respiratory syncytial virus subgroups A and B: A study of frequency, disease severity, and viral load
DeVincenzo, JP
[J]. PEDIATRIC RESEARCH, 2004, 56 (06) : 914 - 917
[6] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
Feltes, TF
Cabalka, AK
Meissner, C
Piazza, FM
Carlin, DA
Top, FH
Connor, EM
Sondheimer, HM
[J]. JOURNAL OF PEDIATRICS, 2003, 143 (04) : 532 - 540
[7] RESPIRATORY SYNCYTIAL AND PARAINFLUENZA VIRUSES
HEILMAN, CA
[J]. JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (03) : 402 - 406
[8] Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis
Legg, JP
Hussain, IR
Warner, JA
Johnston, SL
Warner, JO
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (06) : 633 - 639
[9] Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
Malley, R
DeVincenzo, J
Ramilo, O
Dennehy, PH
Meissner, HC
Gruber, WC
Sanchez, PJ
Jafri, H
Balsley, J
Carlin, D
Buckingham, S
Vernacchio, L
Ambrosino, DM
[J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06) : 1555 - 1561
[10] Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531

← 1 2 →